Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial - The Lancet
4.6
$ 10.00
In stock
(735)
Product Description
Real-world experience of adverse reactions-necessitated rifampicin
PDF) Articles Evaluation of two short standardised regimens for
Tuberculosis treatment: one-shot approach or cascade of regimens
PDF) Investigation of the efficacy of the short regimen for
Evaluation of two short standardized regimens for the treatment of
4.3 Algorithm 3 – DST for second-line drugs for RR-TB or MDR-TB
Long-term treatment outcomes in patients with multidrug-resistant
Antibiotic Steward Bassam Ghanem🆔🌟 on X: 🔥STREAM stage 2
Economic evaluation of shortened, bedaquiline-containing treatment
World Health Organization treatment guidelines for drug-resistant
Long-term treatment outcomes in patients with multidrug-resistant
Timeline of changes to trial design and release of WHO treatment
Bedaquiline- and clofazimine- selected Mycobacterium tuberculosis
Jornal Brasileiro de Pneumologia - Shortened tuberculosis
Mortality from drug-resistant tuberculosis in high-burden
